Tags

Type your tag names separated by a space and hit enter

Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients.
Vaccine. 2006 Mar 06; 24(10):1537-42.V

Abstract

The influence of steroids on the antibody response to a MF59-adjuvanted influenza vaccine in elderly COPD patients has not been studied previously. In the influenza season 2001/02 (October-February) elderly COPD patients were recruited at 14 doctor's offices and our 250-bed hospital. Patients were stratified into three groups according to current treatment regimen: (a) > 10 mg of prednisolone/day (SS); (b) inhaled steroids (IS); (c) no steroid treatment (control group, CG). All patients were vaccinated with the MF59-adjuvanted influenza vaccine. Antibodies against the influenza strains A/H1N1, A/H3N2, and B were measured at baseline, 4 and 24 weeks after vaccination by hemagglutination inhibition (HI) assay. One-hundred and sixty-two patients completed the study (CG n = 42; IS n = 87; SS n = 33). Mean age was 71.3 years (range 60-89). Twenty-one percent of all patients reported local reactions; no serious adverse events were observed. Four weeks after vaccination, mean geometric HI titres (GMT) for A/H1N1, A/H3N and B increased significantly in all groups (p < or = 0.05). After 24 weeks, GMTs to A/H1N1 and A/H3N2 returned to baseline, while GMTs to type B remained significantly higher than baseline in all groups. Significant differences between the groups as regards GMTs, seroconversion (56-89%) or seroprotection rates (64-93%) were not observed. Systemic steroids did not influence the antibody response towards the MF59-adjuvanted influenza vaccine. We found that the strains included in the vaccine showed varying long-term immunogenicity.

Authors+Show Affiliations

de Roux A
Department of Chest and Infectious Diseases, Heckeshorn, Helios Kliniken Emil von Behring, Berlin, Germany. ADeroux@aol.com
Marx A
No affiliation info available
Burkhardt O
No affiliation info available
Schweiger B
No affiliation info available
Borkowski A
No affiliation info available
Banzhoff A
No affiliation info available
Pletz MW
No affiliation info available
Lode H
No affiliation info available

MeSH

Adjuvants, ImmunologicAdrenal Cortex HormonesAgedAged, 80 and overAntibodies, ViralFemaleHemagglutination Inhibition TestsHumansInfluenza VaccinesMaleMiddle AgedPolysorbatesPulmonary Disease, Chronic ObstructiveSqualeneVaccination

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16288937

Citation

de Roux, A, et al. "Impact of Corticosteroids On the Immune Response to a MF59-adjuvanted Influenza Vaccine in Elderly COPD-patients." Vaccine, vol. 24, no. 10, 2006, pp. 1537-42.
de Roux A, Marx A, Burkhardt O, et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine. 2006;24(10):1537-42.
de Roux, A., Marx, A., Burkhardt, O., Schweiger, B., Borkowski, A., Banzhoff, A., Pletz, M. W., & Lode, H. (2006). Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine, 24(10), 1537-42.
de Roux A, et al. Impact of Corticosteroids On the Immune Response to a MF59-adjuvanted Influenza Vaccine in Elderly COPD-patients. Vaccine. 2006 Mar 6;24(10):1537-42. PubMed PMID: 16288937.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. AU - de Roux,A, AU - Marx,A, AU - Burkhardt,O, AU - Schweiger,B, AU - Borkowski,A, AU - Banzhoff,A, AU - Pletz,M W R, AU - Lode,H, Y1 - 2005/10/19/ PY - 2005/07/05/received PY - 2005/09/29/revised PY - 2005/10/07/accepted PY - 2005/11/18/pubmed PY - 2006/5/13/medline PY - 2005/11/18/entrez SP - 1537 EP - 42 JF - Vaccine JO - Vaccine VL - 24 IS - 10 N2 - The influence of steroids on the antibody response to a MF59-adjuvanted influenza vaccine in elderly COPD patients has not been studied previously. In the influenza season 2001/02 (October-February) elderly COPD patients were recruited at 14 doctor's offices and our 250-bed hospital. Patients were stratified into three groups according to current treatment regimen: (a) > 10 mg of prednisolone/day (SS); (b) inhaled steroids (IS); (c) no steroid treatment (control group, CG). All patients were vaccinated with the MF59-adjuvanted influenza vaccine. Antibodies against the influenza strains A/H1N1, A/H3N2, and B were measured at baseline, 4 and 24 weeks after vaccination by hemagglutination inhibition (HI) assay. One-hundred and sixty-two patients completed the study (CG n = 42; IS n = 87; SS n = 33). Mean age was 71.3 years (range 60-89). Twenty-one percent of all patients reported local reactions; no serious adverse events were observed. Four weeks after vaccination, mean geometric HI titres (GMT) for A/H1N1, A/H3N and B increased significantly in all groups (p < or = 0.05). After 24 weeks, GMTs to A/H1N1 and A/H3N2 returned to baseline, while GMTs to type B remained significantly higher than baseline in all groups. Significant differences between the groups as regards GMTs, seroconversion (56-89%) or seroprotection rates (64-93%) were not observed. Systemic steroids did not influence the antibody response towards the MF59-adjuvanted influenza vaccine. We found that the strains included in the vaccine showed varying long-term immunogenicity. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/16288937/Impact_of_corticosteroids_on_the_immune_response_to_a_MF59_adjuvanted_influenza_vaccine_in_elderly_COPD_patients_ DB - PRIME DP - Unbound Medicine ER -